Aytu Biopharma (AYTU) EBT Margin Growth (3y) (2017 - 2026)
Powered by 
Analysis
Aytu Biopharma (AYTU) EBT Margin Growth (3y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | -265.00 |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 636.00 |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 3,137.00 |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | 625.00 |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -2,179.00 |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | -977.00 |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 1,581.00 |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | -861.00 |
| 10 | Aytu Biopharma | 22.49 Mn | -4.22 Mn | 7.60 Mn | -1,351.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -1,351.00 |
| Dec 31, 2025 | -4,432.00 |
| Sep 30, 2025 | 1,668.00 |
| Jun 30, 2025 | -6,985.00 |
| Mar 31, 2025 | 24,091.00 |
| Dec 31, 2024 | 5,231.00 |
| Sep 30, 2024 | 13,672.00 |
| Jun 30, 2024 | 6,242.00 |
| Dec 31, 2023 | 7,035.00 |
| Sep 30, 2023 | -1,009.00 |
| Jun 30, 2023 | 4,624.00 |
| Mar 31, 2023 | 4,031.00 |
| Dec 31, 2022 | 15,912.00 |
| Sep 30, 2022 | 33,993.00 |
| Jun 30, 2022 | 21,629.00 |
| Mar 31, 2022 | -3,125.00 |
| Dec 31, 2021 | 21,068.00 |
| Sep 30, 2021 | 11,634.00 |
| Jun 30, 2021 | 35,299.00 |
| Dec 31, 2020 | 33,580.00 |